

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Slawin Kevin M.</u> (Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 (Street) HOUSTON TX 77030 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/17/2014	3. Issuer Name and Ticker or Trading Symbol <u>BELLICUM PHARMACEUTICALS, INC [BLCM]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">CMO and CTO</p>
		5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	126,764	D	
Common Stock	339,235	I	By the Jordana Slawin 2012 Family Trust ⁽¹⁾
Common Stock	294,117	I	By the Kevin Slawin 2009 Family Trust ⁽²⁾
Common Stock	4,901	I	By the 2009 Slawin Family Partnership ⁽³⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(4)	12/06/2020	Common Stock	48,235	0.51	D	
Stock Option (right to buy)	(5)	11/08/2021	Common Stock	258,823	2.55	D	
Stock Option (right to buy)	(6)	07/30/2023	Common Stock	352,941	2.55	D	
Stock Option (right to buy)	(7)	11/10/2024	Common Stock	108,823	7.47	D	
Warrant to Purchase Series C Preferred Stock (right to buy)	08/22/2014	08/22/2019 ⁽⁸⁾	Series C Preferred Stock	25,277	6	D	
Warrant to Purchase Series C Preferred Stock (right to buy)	08/22/2014	08/22/2019 ⁽⁸⁾	Series C Preferred Stock	71,063	6	I	By the Jordana Slawin 2012 Family Trust ⁽¹⁾
Warrant to Purchase Series C Preferred Stock (right to buy)	08/22/2014	08/22/2019 ⁽⁸⁾	Series C Preferred Stock	61,933	6	I	By the Kevin Slawin 2009 Family Trust ⁽²⁾
Warrant to Purchase Series C Preferred Stock (right to buy)	08/22/2014	08/22/2019 ⁽⁸⁾	Series C Preferred Stock	17,311	6	I	By the 2009 Slawin Family Partnership ⁽³⁾
Series A Convertible Preferred Stock	(9)	(10)	Common Stock	17,135	(10)	I	By the Jordana Slawin 2012 Family Trust ⁽¹⁾
Series A Convertible Preferred Stock	(9)	(10)	Common Stock	16,470	(10)	I	By the Kevin Slawin 2009 Family Trust ⁽²⁾
Series A Convertible Preferred Stock	(9)	(10)	Common Stock	16,904	(10)	I	By the 2009 Slawin Family Partnership ⁽³⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Convertible Preferred Stock	(9)	(10)	Common Stock	65,008	(10)	I	By the 2009 Slawin Family Partnership ⁽³⁾
Series C Convertible Preferred Stock	(9)	(10)	Common Stock	22,875	(10)	D	
Series C Convertible Preferred Stock	(9)	(10)	Common Stock	64,310	(10)	I	By the Jordana Slawin 2012 Family Trust ⁽¹⁾
Series C Convertible Preferred Stock	(9)	(10)	Common Stock	56,048	(10)	I	By the Kevin Slawin 2009 Family Trust ⁽²⁾
Series C Convertible Preferred Stock	(9)	(10)	Common Stock	15,666	(10)	I	By the 2009 Slawin Family Partnership ⁽³⁾

Explanation of Responses:

- The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- The Reporting Person is a managing partner of the 2009 Slawin Family Partnership that owns the reported securities. The Reporting Person has the dispositive power and control over the securities held by such partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- 100% of the shares subject to the stock option are vested and exercisable.
- 25% of the shares subject to the stock option vested and became exercisable on November 9, 2012, with an additional 25% of the shares subject to the stock option vest and become exercisable on each annual anniversary thereafter.
- 34% of the shares subject to the stock option vested and became exercisable on July 31, 2014, with an additional 33% of the shares subject to the stock option vest and become exercisable on each annual anniversary thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on November 11, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- Upon the date immediately following the date of the effectiveness of the initial public offering of the Issuer, on or prior to March 31, 2015, the Warrant will be terminated if not previously exercised.
- The Preferred Stock is convertible at any time.
- Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") is convertible into the Issuer's common stock at a conversion rate of 1 share of common stock for each 1.7 shares of Preferred Stock and has no expiration date.

Remarks:

/s/ Kevin M. Slawin, M.D. 12/17/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Ken Moseley and Alan Musso, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Bellicum Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22nd day of November, 2014.

/s/ Kevin M. Slawin

(Signature)

Kevin M. Slawin, M.D.

(Print Name)